Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07076485 · ClinicalTrials.gov registry record · Phase 2
Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer
A Phase 2 study of Breast Cancer, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 768
- Enrollment target
- 2
- Study locations
NCT07076485: Recruiting Phase 2 study of Breast Cancer, sponsored by M.D. Anderson Cancer Center.
NCT07076485 is a Phase 2 study of Breast Cancer that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 768 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (73% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07076485, a Phase 2 study of Breast Cancer, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 768 participants
- Enrollment target
- 2
- Study locations
Study Summary
To learn about the effects of shorter RNI regimens in patients with breast cance who have had a lumpectomy or mastectomy and who are at higher risk for lower risk for the disease returning.
Conditions Studied
Interventions
- RADIATION Ultrahypofractionated Radiation
- RADIATION Moderately Hypofractionated Radiation
Study Locations (2)
New Jersey
- Cooper Hospital University Medical Center - Voorhees Township
Texas
- The University of Texas M. D. Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 768 participants |
| Start Date | 2025-08-19 |
| Est. Completion | 2031-01-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07076485
The ClinicalTrials.gov registry entry for NCT07076485 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 768 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (73% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Ultrahypofractionated Radiation is the first listed.
NCT07076485 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New Jersey, Texas.
Frequently Asked Questions
What is clinical trial NCT07076485 about?
NCT07076485 is a clinical study titled "Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast Cancer". To learn about the effects of shorter RNI regimens in patients with breast cance who have had a lumpectomy or mastectomy and who are at higher risk for lower risk for the disease returning.
What is the current status of trial NCT07076485?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 768 participants. The study started on 2025-08-19. Estimated completion is 2031-01-01.
What conditions does trial NCT07076485 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT07076485?
The interventions under investigation include: Ultrahypofractionated Radiation (RADIATION), Moderately Hypofractionated Radiation (RADIATION).
Who is sponsoring clinical trial NCT07076485?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07076485 being conducted?
This trial has 2 study locations across New Jersey, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.